What does Precipio do and what are its main business segments?

What factors drove the changes in Precipio's revenue and profit?

What were the key takeaways from Precipio's earnings call?

What guidance did Precipio's management provide for the next earnings period?

What were the key takeaways from Precipio’s earnings call?

What is the revenue and EPS growth rate for Precipio year over year?

What is the market's earnings forecast for Precipio next quarter?

What is Precipio's gross profit margin?

- **Breakthrough Profitability**: Achieved $0.5 million EBITDA and $0.285 million cash from operations, ending reliance on external capital.
- **Revenue Surge**: 30% YoY growth to $6.8 million, with Pathology Services up 20% QoQ and Products Division up 16% QoQ.
- **Margin Expansion**: Pathology Services gross margin at 46%, total company margin at 44%, targeting >50% by mid-2026.
- **Strategic Shift**: Transitioning from cost-cutting to growth investments, including $120,000 lab expansion and technical support roles.
- **Shareholder Value**: Share price tripled year-to-date, with plans to leverage market cap growth for strategic opportunities.

**【CEO Summary Section】**
- **Financial Milestones**: Achieved first-time positive adjusted EBITDA of $469,000 and $285,000 in cash from operations, marking a $433,000 positive cash swing from Q2. Share price has tripled since the start of 2025.
- **Revenue Growth**: Total Q3 revenue reached $6.8 million (30% YoY, 20% QoQ), driven by:
  - **Pathology Services**: $6 million (20% QoQ growth, 46% gross margin up from 43%)
  - **Products Division**: $720,000 (16% QoQ growth, 30% YoY expansion)
- **Gross Margin Expansion**: Overall gross margin improved to 44%, with Pathology Services leading at 46%. Expecting >50% gross margin by mid-2026.
- **Strategic Investments**: 
  - $120,000 annual lab space expansion to separate clinical and product operations
  - Technical support specialist to accelerate customer onboarding, generating $50,000 incremental QoQ revenue
- **Operational Efficiency**: Absorbed 20% revenue growth in Pathology Services without significant fixed cost increases, maintaining margin expansion.
- **Future Priorities**: 
  - Double-digit growth in both divisions
  - Expand margins through scale
  - Invest cash in strategic partnerships and product innovation
  - Enhance investor engagement to drive share price appreciation

Precipio, Inc.(PRPO)-20251118-2025 Q3 Earnings call transcript

- **Revenue Growth**: Pathology Services at 70% annualized, Products up 23% QoQ (100% annualized), with gross margin improving to 43%.
- **Strategic Initiatives**: Backup testing continuity program and distributor pipeline expansion to mitigate customer disruptions.
- **Breakeven Confidence**: On track for 2025 breakeven without capital, despite lab expansion investments.
- **Stock Performance**: 3x QoQ growth driven by financial momentum and increased investor engagement.

**【CEO Summary Section】**
- **Q2 2025 Highlights**: Revenue growth driven by Pathology Services (70% annualized) and Products (23% QoQ, 100% annualized). Gross margin improved to 43% from 39%, with investments in lab expansion and equipment.
- **Breakeven Confidence**: On track to achieve breakeven in 2025 without additional capital, despite strategic investments impacting near-term cash flow.

**【Pathology Services Division】**
- **Revenue Momentum**: July 2025 saw a record $2M+ in single-month revenue (unaudited), with gross margins expected to stabilize at 50% by 2026. Low DSO and high collection rates ensure cash generation.
- **Customer Synergy**: Generates samples critical for Product division R&D, supporting new product development and customer support.

**【Products Division】**
- **Recovery from Disruptions**: Key customers resolved operational issues, resuming revenue growth. New customers added, offsetting prior declines.
- **Continuity Program**: Optional backup testing service for customers during disruptions, maintaining patient care and converting product revenue to service-based during outages.

**【Financial Highlights】**
- **Gross Margin Trend**: Product gross margin decline expected to reverse next quarter; overall company margin improved to 43%.
- **Cash Management**: Strategic investments (lab expansion, equipment) modestly delayed breakeven but align with long-term growth.

**【Warrant Conversion】**
- **Dilution Mitigation**: Structured 300,000 warrant exercise to issue 100,000 shares for $1.2M cash, with remaining 200,000 exercised cashlessly to minimize share dilution.
- **Shareholder Value**: Focused on reducing market impact while maintaining capital flexibility.

**【Stock Performance】**
- **Triple-QoQ Growth**: Driven by improved financials (3+ quarters of growth, margin expansion) and increased investor engagement post-stealth mode.
- **Storytelling Strategy**: Active investor outreach and conference participation to build market awareness and demand.

Precipio, Inc. (PRPO) Q2 2025 Earnings Call Transcript

- **Revenue growth outperforms expectations**: 43% YoY to $4.9M, despite seasonal QoQ decline
- **Gross margin expansion**: 43% company-wide (vs 27% YoY), driven by lab efficiency and scale
- **Key milestones**:
  - $250k quarterly uplift from MolDx NGS approval
  - 7-figure customer pipeline in Product division
  - $0.5M non-recurring COVID relief funds
- **Cash flow recovery**: On track for Q2/Q3 positive cash flow
- **Operational discipline**: Flat OpEx ($3M/quarter) vs +43% revenue growth

**【CEO Opening Remarks】**
- Q1 2025 revenue: $4.9 million (43% YoY growth, 9.5% QoQ decline due to seasonal trends)
- Adjusted EBITDA: -$108,000 (92% YoY improvement)
- Cash use: $44,000 (93% YoY reduction)
- Net cash used: $372,000 (49% YoY improvement)

**【Pathology Services Division】**
- Test volume up 46%, revenue +53% YoY
- Gross margin expansion to 42% (from 24% YoY) driven by:
  - Batch efficiency (e.g., $200 control cost spread over 20 samples vs 5)
  - Equipment scale (fixed costs amortized over more samples)
  - Staff training (e.g., reagent pipetting accuracy)
- Sequential QoQ decline explained by Medicare deductible reset impact

**【Product Division】**
- New customer onboarding and 2 new panel launches
- Gross margin improvement to 51% (from 37% YoY) due to:
  - Shelf-life testing optimization (12% of batch vs 6%)
  - FDA LBP regulatory clarity enabling pipeline conversions
- Potential $250k quarterly revenue from MolDx NGS approval

**【Financial Highlights】**
- Combined company gross margin: 43% (vs 27% YoY)
- Non-recurring cash inflows:
  - $1.1M Change Healthcare relief (repaid $200k YTD)
  - $400k COVID relief funds received
- Expect Q2/Q3 return to positive cash flow

**【2025 Outlook】**
- Pathology: Mid-40% margin stabilization
- Products: Accelerated pipeline with 7-figure customer potential
- Overall: Sequential revenue acceleration in H2


Precipio, Inc. (PRPO) Q1 2025 Earnings Call Transcript

- **Breakeven achieved**: Q4 2024 marks first profitable quarter with positive cash flow.
- **Revenue growth**: 22% YoY, targeting $5.6M product run rate by end-2025 via distributors.
- **New leadership**: Steve Miller reappointed to drive product sales and strategic partnerships.
- **Transition to growth**: Shift from cost-cutting to investment in scalable solutions.

**【CEO Opening Remarks】**
- Achieved breakeven in Q4 2024 with positive EBITDA and cash flow, marking a turning point toward profitability.
- 2024 revenue growth: 26% QoQ and 22% YoY, driven by disciplined financial management and reduced cash burn.

**【Business Division Performance】**
- **Pathology Services**: Exceeded $1.3M/month breakeven in Q4, targeting $25M annual run rate by end-2025. Serves as cash flow generator and R&D platform.
- **Products Division**: Q4 revenue $700K (same as Q3), challenges include regulatory delays (e.g., LOD updates), lab workflow issues, and staffing gaps. 2025 focus: scale via distributors, target $2.8M→$5.6M run rate.

**【2025 Strategic Initiatives】**
- Reappoint Steve Miller as Chief Commercial Officer to accelerate product sales.
- Shift to 'offensive' mindset: invest in growth, expand customer base for smoother revenue trajectory.
- Enhance investor relations through industry conferences, analyst outreach, and financial guidance.

**【Challenges & Solutions】**
- Regulatory challenges: Anticipate changes (e.g., LOD updates) and adapt faster than competitors.
- Lab workflow: Develop checklists to identify and mitigate risks during onboarding.
- Customer diversity: Grow pipeline to leverage law of large numbers for stable growth.


Actual			-2.2	-2.8	-1.6		-4	-2.6			-0.83	-0.42				-0.05
Forecast			-1.8	-2	-2	-1.4	-1	-2.6	-0.93	-0.7	-0.05	0.4	0.74
Surprise	0.00%	0.00%	-22.22%	-40.00%	+20.00%	0.00%	-300.00%	0.00%	0.00%	0.00%	-1560.00%	-205.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Actual	--	--	1.90M	2.30M	2.25M	--	2.45M	2.82M	--	--	4.44M	5.21M	--	--	--	6.77M	--
Forecast	--	--	2.25M	2.30M	1.89M	3.20M	4.81M	760.00K	4.36M	4.88M	4.40M	7.29M	8.01M	--	--	--	--
Surprise	0.00%	0.00%	-15.56%	0.00%	+18.59%	0.00%	-49.08%	+270.66%	0.00%	0.00%	+0.93%	-28.59%	0.00%	0.00%	0.00%	0.00%	0.00%

PRPO

PRPO fundamentals

PRPO Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

PRPO

PRPO fundamentals

PRPO Q4 2025 Earnings Preview

Earnings Call

PRPO Earnings Call Summary for Q4/20255:00 PM on Apr 2, 2026

PRPO Earnings Call Summary for Q3/20255:00 PM on Nov 17, 2025

PRPO Earnings Call Summary for Q2/20255:00 PM on Aug 14, 2025

PRPO Earnings Call Summary for Q1/20255:00 PM on May 15, 2025

PRPO Earnings Call Summary for Q4/20245:00 PM on Mar 31, 2025

You can ask Aime